Generation of a FasL-based Proapoptotic Fusion Protein Devoid of Systemic Toxicity due to Cell-surface Antigen-restricted Activation
Authors:
- Dafne MüllerDMDafne Müller
- Jeannette GerspachJGJeannette Gerspach
- Constance Assohou-LutyCAConstance Assohou-Luty
- Gabriele SassGSGabriele Sass
- Gisa TiegsGTGisa Tiegs
- Klaus PfizenmaierKPKlaus Pfizenmaier
- Harald WajantHWHarald Wajant
Open Access
- 1 August 2003
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (34) , 32077-32082
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factorOncogene, 2002
- The Fas Signaling Pathway: More Than a ParadigmScience, 2002
- Fas receptor‐mediated apoptosis: a clinical application?The Journal of Pathology, 2001
- Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivativeOncogene, 2001
- Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.Journal of Clinical Investigation, 1997
- Metalloproteinase-mediated release of human Fas ligand.Journal of Experimental Medicine, 1995
- Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.Journal of Experimental Medicine, 1995
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- Lethal effect of the anti-Fas antibody in miceNature, 1993
- Monoclonal Antibody-Mediated Tumor Regression by Induction of ApoptosisScience, 1989